CATEGORY: HEART & CIRCULATION
A daily pill called finerenone reduced worsening heart-failure episodes and cardiovascular deaths, taken together, by 16% in people whose hearts pump normally but have grown stiff.1 In absolute terms, that meant 14.9 such events for every 100 patients each year with finerenone and 17.7 with placebo, over nearly three years of follow-up in 6,001 adults. The gain came almost entirely from fewer heart-failure flare-ups. Deaths alone didn’t fall.
A Heart That Squeezes Fine but Fills Poorly
Heart failure usually calls to mind a weak, baggy pump. This trial, named FINEARTS-HF, enrolled the other kind: hearts with a preserved or only mildly reduced squeeze, whose walls have stiffened so they fill badly. Fluid backs up, legs swell, stairs become mountains. It’s the form that dominates in older adults, especially women, and for decades almost nothing tested against it worked. Participants averaged 72 years old. Each was handed a bottle by lottery, real finerenone or an identical dummy, on top of their usual medicines, and neither they nor their doctors learned which until the end.
Fewer Hospital Spirals, the Same Number of Deaths
Over a median of 32 months, the finerenone group racked up 842 worsening heart-failure events, mostly hospitalizations, against 1,024 in the placebo group. Cardiovascular death on its own was not significantly different: 8.1% versus 8.7%. So the honest reading is a drug that keeps a stiff-hearted person out of the hospital spiral more often, not one shown to extend life. Symptom scores nudged up by about 1.6 points on a 100-point quality-of-life scale, a small average difference. The main price was potassium. The mineral climbed too high in 14.3% of people on finerenone versus 6.9% on placebo, which is why the drug comes with routine blood tests.
Where This Lands in the Treatment Landscape
Finerenone blocks a hormone signal that drives salt retention and scarring in the heart and kidneys, and it was first approved for chronic kidney disease in diabetes. The result carries history on its back: a related, older drug, spironolactone, narrowly missed on a similar composite endpoint in a 2014 trial, leaving the drug class in limbo for a decade.2 This trial was designed to ask the question again with more patients, and it returned a clear answer. US regulators approved finerenone for this form of heart failure in 2025, making it one of the few pills with trial-proven benefit for a condition that long had none.
Key Takeaways
- Finerenone cut the combined rate of worsening heart-failure events and cardiovascular deaths by 16% in heart failure with preserved or mildly reduced pumping, about 2.8 fewer events per 100 patients per year.
- The benefit came from fewer flare-ups and hospitalizations; deaths by themselves didn’t drop.
- High potassium roughly doubled on the drug, so treatment involves ongoing blood monitoring.
- An older cousin, spironolactone, had narrowly missed in a 2014 trial; this larger, stricter test is what earned the drug class its place in stiff-heart failure.
References
- Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. 2024;391(16):1475–1485. link
- Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. The New England Journal of Medicine. 2014;370(15):1383–1392. link